Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Dianthus Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
252828 108
(CUSIP Number)
Atlas Venture
Attention: Ommer Chohan, Chief Financial Officer
300 Technology Square, 8th Floor
Cambridge, MA 02139 USA
(857) 201-2700
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
September 11, 2023
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. x
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP 252828 108 | Page 2 of 10 |
| 1 |
NAMES OF REPORTING PERSONS: ATLAS VENTURE FUND X, L.P. | ||||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ¨ (b) x | ||||
| 3 | SEC USE ONLY: | ||||
| 4 |
SOURCE OF FUNDS (SEE INSTRUCTIONS): WC | ||||
| 5 |
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨ | ||||
| 6 |
CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER: 0 | |||
| 8 |
SHARED VOTING POWER: 166,5011 | ||||
| 9 |
SOLE DISPOSITIVE POWER: 0 | ||||
| 10 |
SHARED DISPOSITIVE POWER: 166,5011 | ||||
| 11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 166,5011 | ||||
| 12 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨ | ||||
| 13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 1.1%2 | ||||
| 14 |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): PN | ||||
| 1 | As described in Item 5 below, Atlas Venture Fund X, L.P., a Delaware limited partnership (“Atlas X”) beneficially owns 166,501 shares of the Issuer’s Common Stock that are directly held by Atlas X. Atlas Venture Associates X, L.P., a Delaware limited partnership (“AVA X LP”) is the general partner of Atlas X and Atlas Venture Associates X, LLC, a Delaware limited liability company (“AVA X LLC” and together with Atlas X and AVA X LP, the “Fund X Reporting Persons”) is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has voting and dispositive power over the shares held by Atlas X. As such, each of the Fund X Reporting Persons share voting and dispositive power with respect to the shares held by Atlas X. |
| 2 | This percentage is calculated based upon 14,817,700 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 12, 2023. |
| CUSIP 252828 108 | Page 3 of 10 |
| 1 |
NAMES OF REPORTING PERSONS: ATLAS VENTURE ASSOCIATES X, L.P. | ||||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ¨ (b) x | ||||
| 3 | SEC USE ONLY: | ||||
| 4 |
SOURCE OF FUNDS (SEE INSTRUCTIONS): AF | ||||
| 5 |
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨ | ||||
| 6 |
CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER: 0 | |||
| 8 |
SHARED VOTING POWER: 186,0891 | ||||
| 9 |
SOLE DISPOSITIVE POWER: 0 | ||||
| 10 |
SHARED DISPOSITIVE POWER: 186,0891 | ||||
| 11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 186,0891 | ||||
| 12 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨ | ||||
| 13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 1.3%2 | ||||
| 14 |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): PN | ||||
| 1 | As described in Item 5 below, AVA X LP and AVA X LLC beneficially own 186,089 shares of the Issuer’s Common Stock (166,501 shares of the Issuer's Common Stock that are directly held by Atlas X and 19,588 shares of the Issuer’s Common Stock that are directly held by AVA X LP). AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has voting and dispositive power over the shares held by Atlas X and AVA X LLC has voting and dispositive power over the shares held by AVA X LP. As such, each of the Fund X Reporting Persons share voting and dispositive power with respect to the shares held by Atlas X. |
| 2 | This percentage is calculated based upon 14,817,700 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 12, 2023. |
| CUSIP 252828 108 | Page 4 of 10 |
| 1 |
NAMES OF REPORTING PERSONS: Atlas Venture Associates X, LLC | ||||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ¨ (b) x | ||||
| 3 | SEC USE ONLY: | ||||
| 4 |
SOURCE OF FUNDS (SEE INSTRUCTIONS): AF | ||||
| 5 |
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨ | ||||
| 6 |
CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER: 0 | |||
| 8 |
SHARED VOTING POWER: 186,0891 | ||||
| 9 |
SOLE DISPOSITIVE POWER: 0 | ||||
| 10 |
SHARED DISPOSITIVE POWER: 186,0891 | ||||
| 11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 186,0891 | ||||
| 12 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨ | ||||
| 13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 1.3%2 | ||||
| 14 |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): OO | ||||
| 1 | As described in Item 5 below, AVA X LP and AVA X LLC beneficially own 186,089 shares of the Issuer’s Common Stock (166,501 shares of the Issuer's Common Stock that are directly held by Atlas X and 19,588 shares of the Issuer’s Common Stock that are directly held by AVA X LP). AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has voting and dispositive power over the shares held by Atlas X and AVA X LLC has voting and dispositive power over the shares held by AVA X LP. As such, each of the Fund X Reporting Persons share voting and dispositive pow er with respect to the shares held by Atlas X. |
| 2 | This percentage is calculated based upon 14,817,700 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 12, 2023. |
| CUSIP 252828 108 | Page 5 of 10 |
| 1 |
NAMES OF REPORTING PERSONS: Atlas Venture Opportunity Fund I, L.P. | ||||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ¨ (b) x | ||||
| 3 | SEC USE ONLY: | ||||
| 4 |
SOURCE OF FUNDS (SEE INSTRUCTIONS): WC | ||||
| 5 |
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨ | ||||
| 6 |
CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER: 0 | |||
| 8 |
SHARED VOTING POWER: 50,7811 | ||||
| 9 |
SOLE DISPOSITIVE POWER: 0 | ||||
| 10 |
SHARED DISPOSITIVE POWER: 50,7811 | ||||
| 11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 50,7811 | ||||
| 12 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨ | ||||
| 13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 0.3%2 | ||||
| 14 |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): PN | ||||
| 1 | As described in Item 5 below, Atlas Venture Opportunity Fund I, L.P., a Delaware limited partnership (“AVOF”) beneficially owns 50,781 shares of the Issuer’s Common Stock that are directly held by AVOF. Atlas Venture Associates Opportunity I, L.P., a Delaware limited partnership (“AVAO LP”) is the general partner of AVOF and Atlas Venture Associates Opportunity I, LLC, a Delaware limited liability company (“AVAO LLC” and together with AVOF and AVAO LP, the “Opportunity Fund Reporting Persons”) is the general partner of AVAO LP. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVOF. |
| 2 | This percentage is calculated based upon 14,817,700 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 12, 2023. |
| CUSIP 252828 108 | Page 6 of 10 |
| < font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 |
NAMES OF REPORTING PERSONS: Atlas Venture Associates Opportunity I, L.P. | ||||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ¨ (b) x | ||||
| 3 | SEC USE ONLY: | ||||
| 4 |
SOURCE OF FUNDS (SEE INSTRUCTIONS): AF | ||||
| 5 |
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨ | ||||
| 6 |
CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER: 0 | |||
| 8 |
SHARED VOTING POWER: 50,8901 | ||||
| 9 |
SOLE DISPOSITIVE POWER: 0 | ||||
| 10 |
SHARED DISPOSITIVE POWER: 50,8901 | ||||
| 11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 50,8901 | ||||
| 12 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨ | ||||
| 13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 0.3%2 | ||||
| 14 |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): PN | ||||
| 1 | As described in Item 5 below, AVAO LP and AVAO LLC beneficially own 50,890 shares of the Issuer’s Common Stock (50,781 shares of the Issuer's Common Stock that are directly held by AVOF and 109 shares of the Issuer’s Common Stock that are directly held by AVAO LP). AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVOF. |
| 2 | This percentage is calculated based upon 14,817,700 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 12, 2023. |
| CUSIP 252828 108 | Page 7 of 10 |
| 1 |
NAMES OF REPORTING PERSONS: Atlas Venture Associates Opportunity I, LLC | ||||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) ¨ (b) x | ||||
| 3 | SEC USE ONLY: | ||||
| 4 |
SOURCE OF FUNDS (SEE INSTRUCTIONS): AF | ||||
| 5 |
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨ | ||||
| 6 |
CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER: 0 | |||
| 8 |
SHARED VOTING POWER: 50,8901 | ||||
| 9 |
SOLE DISPOSITIVE POWER: 0 | ||||
| 10 |
SHARED DISPOSITIVE POWER: 50,8901 | ||||
| 11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 50,8901 | ||||
| 12 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨ | ||||
| 13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 0.3%2 | ||||
| 14 |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): OO | ||||
| 1 | As described in Item 5 below, AVAO LP and AVAO LLC beneficially own 50,890 shares of the Issuer’s Common Stock (50,781 shares of the Issuer's Common Stock that are owned by AVOF and 109 shares of the Issuer’s Common Stock that are directly held by AVAO LP). AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVOF. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVOF. |
| 2 | This percentage is calculated based upon 14,817,700 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 12, 2023. |
| CUSIP 252828 108 | Page 8 of 10 |
INTRODUCTION
This Amendment No. 3 to Schedule 13D (“Amendment No. 3”) is being filed as an amendment to the statement on Schedule 13D relating to common stock, par value $0.001 per share (the “Common Stock”) of Dianthus Therapeutics, Inc. (formerly, Magenta Therapeutics, Inc.), a Delaware corporation (the “Issuer” or “Dianthus”), as filed with the Securities and Exchange Commission (the “SEC”) on July 14, 2020 (the “Initial Schedule 13D”) and later amended on February 17, 2021 (“Amendment No. 1” and May 5, 2022 (“Amendment No. 2”), and together with the Initial Schedule 13D, the “Prior Schedule 13D”). This Amendment No. 3 is being filed to report the dilution in the Reporting Persons’ beneficial ownership resulting from the Dianthus Merger (as defined below). All capitalized terms not otherwise defined herein shall have the meanings ascribed to the terms in the Prior Schedule 13D. The Prior Schedule 13D is hereby amended and supplemented as follows and, except as expressly amended below, the Prior Schedule 13D remains in full force and effect.
ITEM 1. SECURITY AND ISSUER
The class of equity securities to which this Schedule 13D relates is common stock, par value $0.001 per share (the “Common Stock”) of Dianthus Therapeutics, Inc. (formerly, Magenta Therapeutics, Inc.), a Delaware corporation (the “Issuer” or “Dianthus”). The principal executive offices of the Issuer are located at 7 Times Square, 43rd Floor, New York, New York 10036.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
On September 11, 2023, the Issuer completed the transactions contemplated by the Agreement and Plan of Merger , dated as of May 2, 2023 (the “Dianthus Merger Agreement”), by and among the Issuer, Dianthus Therapeutics, Inc., a Delaware corporation, (“Dianthus”) and Dio Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (“Merger Sub”), pursuant to which, among other matters, Merger Sub merged with and into Dianthus, with Dianthus continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the Dianthus Merger Agreement (the “Dianthus Merger”). In connection with the closing of the Dianthus Merger Agreement, the Issuer changed its name to Dianthus Therapeutics, Inc.
In connection with the Dianthus Merger, the Issuer effected a reverse split of its Common Stock (the “Reverse Stock Split”), pursuant to which each 16 shares of Common Stock issued and outstanding immediately prior to the Reverse Stock Split were automatically without further action on the part of the Issuer or any holders of such Common Stock, reclassified, combined, converted and changed into one share of Common Stock.
| CUSIP 252828 108 | Page 10 of 10 |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: September 15, 2023
| ATLAS VENTURE FUND X, L.P. | ||
| By: Atlas Venture Associates X, L.P., its general partner | ||
| By: Atlas Venture Associates X, LLC, its general partner | ||
| By: | /s/ Ommer Chohan | |
| Name: Ommer Chohan | ||
| Title: Chief Financial Officer | ||
| ATLAS VENTURE ASSOCIATES X, L.P. | ||
| By: Atlas Venture Associates X, LLC, its general partner | ||
| By: | /s/ Ommer Chohan | |
| Name: Ommer Chohan | ||
| Title: Chief Financial Officer | ||
| ATLAS VENTURE ASSOCIATES X, LLC | ||
| By: | /s/ Ommer Chohan | |
| Name: Ommer Chohan | ||
| Title: Chief Financial Officer | ||
| ATLAS VENTURE OPPORTUNITY FUND I, L.P. | ||
| By: Atlas Venture Associates Opportunity I, L.P., its general partner | ||
| By: Atlas Venture Associates Opportunity I, LLC, its general partner | ||
| By: | /s/ Ommer Chohan | |
| Name: Ommer Chohan | ||
| Title: Chief Financial Officer | ||
| ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P. | ||
| By: Atlas Venture Associates Opportunity I, LLC, its general partner | ||
| By: | /s/ Ommer Chohan | |
| Name: Ommer Chohan | ||
| Title: Chief Financial Officer | ||
| ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC | ||
| By: | /s/ Ommer Chohan | |
| Name: Ommer Chohan | ||
| Title: Chief Financial Officer | ||